Dr. Philip Schein, President of The Schein Group, is widely recognized as a leading international authority in the treatment of cancer. He also serves as Visiting Professor in Cancer Pharmacology at the University of Oxford. He was the founder and former Chairman and CEO of US Bioscience. His previous appointments include: Vice President of Worldwide Clinical Research and Development and Director of the Laboratory of Molecular Medicine at SmithKline & French Laboratories, Professor of Medicine and Pharmacology and Scientific Director of the Vincent T. Lombardi Cancer Research Center at Georgetown University School of Medicine and Senior Investigator and Head of the Clinical Pharmacology Section of the Medicine Branch, National Cancer Institute, Bethesda, Maryland.

Dr. Schein has authored over 350 scientific articles and texts and has been awarded 11 patents. He was appointed to the National Cancer Advisory Board by President Clinton. He served as President of the American Society of Clinical Oncology and has chaired the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee. He has also served as a member of the Board of Directors of the American Board of Internal Medicine, where he chaired the Medical Oncology Committee. Dr. Schein received his AB degree from Rutgers College and his MD from the Upstate Medical University. His post-graduate education was untaken at Harvard, Oxford and the National Cancer Institute. Dr. Schein is a Fellow of the Royal College of Physicians of London and the Royal College of Physicians and Surgeons of Glasgow.